Clinicopathological features of differentiated thyroid carcinoma referred to radioiodine therapy at Tripoli Medical Center

2018 ◽  
Vol 15 (1) ◽  
pp. 3
Author(s):  
HawaJuma El-Shareif
Keyword(s):  
Thyroid Carcinoma ◽  
Radioiodine Therapy ◽  
Medical Center ◽  
Differentiated Thyroid Carcinoma ◽  
Clinicopathological Features

Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?

2002 ◽  
Vol 57 (1) ◽  
pp. 117-124 ◽  
Author(s):  
Jeroen Schaap ◽  
Carmen F. A. Eustatia-Rutten ◽  
Marcel Stokkel ◽  
Thera P. Links ◽  
Michaela Diamant ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma

Evaluation of Parotid Salivary Gland Echo Texture by Ultrasound Examinations and Correlation With Whole‐Body Scintigraphy After Radioiodine Therapy in Patients With Differentiated Thyroid Carcinoma

2020 ◽  
Vol 39 (9) ◽  
pp. 1811-1818
Author(s):  
Graziele Aparecida Simões Lima ◽  
Rossana Verónica Mendoza López ◽  
Ricardo Miguel Costa Freitas ◽  
Jose Willegaignon ◽  
Marcelo Tatit Sapienza ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Thyroid Carcinoma ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Whole Body ◽  
Parotid Salivary Gland

scholarly journals Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Ivana Zagar ◽  
Andreja A. Schwarzbartl-Pevec ◽  
Barbara Vidergar-Kralj ◽  
Rika Horvat ◽  
Nikola Besic
Keyword(s):  
Thyroid Carcinoma ◽  
Total Thyroidectomy ◽  
Physical Condition ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Therapeutic Benefit ◽  
The Poor ◽  
Radioiodine Ablation ◽  
Recombinant Human Thyrotropin ◽  
Tsh Stimulation

Our aim was to test the efficacy of 131-I therapy (RIT) using recombinant human TSH (rhTSH) in patients with differentiated thyroid carcinoma (DTC) in whom endogenous TSH stimulation was not an option due to the poor patient's physical condition or due to the disease progression during L-thyroxin withdrawal. The study comprised 18 patients, who already have undergone total or near-total thyroidectomy and radioiodine ablation and 0–12 (median 5) RITs after L-thyroxin withdrawal. Our patients received altogether 44 RITs using rhTSH while on L-thyroxin. Six to 12 months after the first rhTSH-aided RIT, PR and SD was achieved in 3/18 (17%) and 4/18 patients (22%), respectively. In most patients (n= 12; 61%) disease progressed despite rhTSH-aided RITs. As a conclusion, rhTSH-aided RIT proved to add some therapeutic benefit in 39% our patients with metastatic DTC, who otherwise could not be efficiently treated with RIT.

Sign in / Sign up

Export Citation Format

Share Document